PRX-08066 (original) (raw)
PRX-08066 is a drug discovered and developed by Predix (later Epix) Pharmaceuticals [Dale S. Dhanoa et al. Patent US 7,030,240 B2], which acts as a potent and selective antagonist at the serotonin 5-HT2B receptor, with a 5-HT2B binding affinity (Ki) of 3.4nM, and high selectivity over the closely related 5-HT2A and 5-HT2C receptors and other receptor targets. PRX-08066 and other selective 5-HT2B antagonists are being researched for the treatment of pulmonary arterial hypertension, following the discovery that the potent 5-HT2B agonist norfenfluramine produces pulmonary arterial hypertension and subsequent heart valve damage. In animal studies, PRX-08066 has been found to reduce several key indicators of pulmonary arterial hypertension and improved cardiac output, with similar efficacy to e
| Property | Value |
|---|---|
| dbo:abstract | PRX-08066 is a drug discovered and developed by Predix (later Epix) Pharmaceuticals [Dale S. Dhanoa et al. Patent US 7,030,240 B2], which acts as a potent and selective antagonist at the serotonin 5-HT2B receptor, with a 5-HT2B binding affinity (Ki) of 3.4nM, and high selectivity over the closely related 5-HT2A and 5-HT2C receptors and other receptor targets. PRX-08066 and other selective 5-HT2B antagonists are being researched for the treatment of pulmonary arterial hypertension, following the discovery that the potent 5-HT2B agonist norfenfluramine produces pulmonary arterial hypertension and subsequent heart valve damage. In animal studies, PRX-08066 has been found to reduce several key indicators of pulmonary arterial hypertension and improved cardiac output, with similar efficacy to established drugs for this condition such as bosentan, sildenafil, beraprost and iloprost. It is also being researched for potential anti-cancer applications, due to its ability to inhibit fibroblast activation. (en) |
| dbo:casNumber | 866206-54-4 |
| dbo:fdaUniiCode | 82SK298EBU |
| dbo:pubchem | 11502243 |
| dbo:thumbnail | wiki-commons:Special:FilePath/PRX-08066_structure.png?width=300 |
| dbo:wikiPageID | 29732054 (xsd:integer) |
| dbo:wikiPageLength | 3408 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1087723184 (xsd:integer) |
| dbo:wikiPageWikiLink | dbc:5-HT2B_antagonists dbr:Beraprost dbr:Bosentan dbr:Sildenafil dbr:Pulmonary_arterial_hypertension dbr:Dissociation_constant dbr:5-HT2A_receptor dbr:5-HT2B_receptor dbr:5-HT2C_receptor dbr:Norfenfluramine dbr:Receptor_(biochemistry) dbr:Fibroblast dbr:Iloprost dbr:Serotonin dbr:Antagonist_(pharmacology) |
| dbp:c | 19 (xsd:integer) |
| dbp:casNumber | 866206 (xsd:integer) |
| dbp:chemspiderid | 9677045 (xsd:integer) |
| dbp:cl | 1 (xsd:integer) |
| dbp:f | 1 (xsd:integer) |
| dbp:h | 17 (xsd:integer) |
| dbp:iupacName | 5 (xsd:integer) |
| dbp:n | 5 (xsd:integer) |
| dbp:pubchem | 11502243 (xsd:integer) |
| dbp:s | 1 (xsd:integer) |
| dbp:smiles | s3c2ncncNC4CCNCccc1C#N (en) |
| dbp:unii | 82 (xsd:integer) |
| dbp:width | 220 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Drugbox dbt:Nervous-system-drug-stub dbt:Reflist dbt:Serotonergics dbt:Short_description dbt:Cascite dbt:Fdacite |
| dct:subject | dbc:5-HT2B_antagonists |
| gold:hypernym | dbr:Drug |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatMolecularFormulas yago:Abstraction100002137 yago:Adversary109773245 yago:CausalAgent100007347 yago:Communication100033020 yago:Formula106816935 yago:LivingThing100004258 yago:Message106598915 yago:MolecularFormula106817173 yago:Object100002684 yago:Organism100004475 yago:Person100007846 yago:PhysicalEntity100001930 yago:YagoLegalActor yago:YagoLegalActorGeo dbo:Drug yago:Statement106722453 yago:Whole100003553 yago:Wikicat5-HT2BAntagonists |
| rdfs:comment | PRX-08066 is a drug discovered and developed by Predix (later Epix) Pharmaceuticals [Dale S. Dhanoa et al. Patent US 7,030,240 B2], which acts as a potent and selective antagonist at the serotonin 5-HT2B receptor, with a 5-HT2B binding affinity (Ki) of 3.4nM, and high selectivity over the closely related 5-HT2A and 5-HT2C receptors and other receptor targets. PRX-08066 and other selective 5-HT2B antagonists are being researched for the treatment of pulmonary arterial hypertension, following the discovery that the potent 5-HT2B agonist norfenfluramine produces pulmonary arterial hypertension and subsequent heart valve damage. In animal studies, PRX-08066 has been found to reduce several key indicators of pulmonary arterial hypertension and improved cardiac output, with similar efficacy to e (en) |
| rdfs:label | PRX-08066 (en) |
| owl:sameAs | freebase:PRX-08066 yago-res:PRX-08066 wikidata:PRX-08066 dbpedia-sh:PRX-08066 dbpedia-sr:PRX-08066 https://global.dbpedia.org/id/49Sjs |
| prov:wasDerivedFrom | wikipedia-en:PRX-08066?oldid=1087723184&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/PRX-08066_structure.png |
| foaf:isPrimaryTopicOf | wikipedia-en:PRX-08066 |
| is dbo:wikiPageRedirects of | dbr:C19H17ClFN5S |
| is dbo:wikiPageWikiLink of | dbr:Epix_Pharmaceuticals dbr:C19H17ClFN5S dbr:5-HT2B_receptor |
| is foaf:primaryTopic of | wikipedia-en:PRX-08066 |
